Strategic Partnerships GlycoSeLect has a history of international distribution partnerships with MJS BioLynx in Canada and DBA Italia, indicating a receptiveness to collaboration. This suggests sales opportunities through channel partners and regional distributors to accelerate market reach in biopharma, diagnostics, and vaccines.

Biotech Niche Specialized Recombinant Prokaryotic Lectins for glycan analysis and purification position the company in a high-value niche within glycoscience, glycobiology, and biotherapeutics. Target markets include biopharma manufacturers, diagnostics labs, and vaccine developers seeking scalable, cost-effective glycan tools.

Global Expansion Active international partnerships and a Dublin base suggest growth ambitions beyond Ireland. Potential sales opportunities exist through European Union biotech clusters, North American distributors, and emerging markets seeking robust glycan analysis capabilities for bioprocessing and quality control.

Small Team Agility With a compact team (2-10 employees) and venture funding activity, GlycoSeLect may be highly agile in product iterations and custom collaborations. This can be leveraged for fast pilots, early-access programs, and joint development agreements with pharma and contract research organizations.

Revenue Growth Potential Current revenue is in the zero-to-one million range, indicating an opportunity to position value-led offerings around scalable production and high-purity RPLs. Focus on case studies around biomarker discovery, diagnostics partnerships, and biotherapeutics manufacturing to unlock pilot sales and larger multi-year deals.